Cover Image


Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system

出版商 Insight Pharma Reports 商品編碼 337544
出版日期 內容資訊 英文 74 Pages
Back to Top
生物製造業功能的策略:彈性、可伸縮及有效率的生物製造業系統的開發 Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system
出版日期: 2015年08月31日 內容資訊: 英文 74 Pages




第1章 調查焦點

第2章 生物製造業的歷史

第3章 shinguruyuzu的生物製造業

  • 單用的生物製造業的發明,歷史,及影響
  • 市場現狀及實行
  • 單用技術的優點
  • 結論


第4章 擴大功能及彈性的策略

  • 境外外包

第5章 影響功能的外部要素、課題,及機會

第6章 營運上出色的點及降低成本

第7章 生物製造業產業、專門的職業的未來


第8章 市場趨勢、預測如何帶給生產範式影響

  • 採訪
  • 調查結果
  • Insight Pharma Reports的生物製造業功能的策略的相關調查結果


Cambridge Healthtech 關於Institute



The newly published Insight Pharma Reports, ‘Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable, and Lean Biomanufacturing System Report’, focus on the need for a more reactive and dynamic biomanufacturing approach than is the current industry standard.

Biomanufacturing is common practice in the life sciences industry and has been continually developed and improved for the last two decades. However, as blockbuster drugs reach the end of their patents, treatment is evolving to become more patient-centric and personalized. The mapping of the human genome has allowed for sophisticated and effective new genetic markers and diagnostic methods to be developed, meaning that personalized medicine is becoming a reality. This has a direct impact on manufacturing, with long-term expected production paradigm shifts in the shape of near-patient manufacturing. Moreover, the rise in incidence of viral pandemics has driven a need for quick set-up, disposable, transportable biomanufacturing. This was a contributing factor to Tamiflu being first to market and will very likely be key in the race to stop the Ebola pandemic.

In addition to covering background information on biomanufacturing and capacity approaches, this report will highlight several technologies, methodologies, and business strategies that can be implemented to improve the capacity and flexibility of biomanufacturing.

Included in this Report:

  • Detailed the history of biomanufacturing development and the direction for the coming decade
  • Overview of single-use biomanufacturing techniques and trends, outlining the importance of reactive biomanufacturing
  • Insight into the Ebola vaccine clinical development, as well as the validation process.
  • Specific capacity-enhancing approaches ranging from technology solutions to business strategy
  • Examine the overarching industry pressures that are driving capacity needs, the subsequent regulatory compliance, and where the biggest efficiency and productivity savings can be realized.
  • Explore the scale-up of biomanufacturing processes to serve commercial scale production, which is currently a major limiting factor in the maturity of this field, and how commercialization of certain therapeutics and regenerative medicines is severely limited by the lack of progression here.
  • Ventures into the realm of lean thinking and continuous manufacturing methodologies and their application in the field of biomanufacturing with a secondary look at the potential of combining modular facilities with disposable biomanufacturing systems and the technical requirements and advances.
  • Details a considerable amount with regard to technology transfer and the specific issues relating to biomanufacturing, and outlines some solutions and new approaches to knowledge transfer
  • Takes a wider view of the context, importance, and impact of biomanufacturing and its capacity to provide a solution to several biotechnology industry challenges.
  • Provides insight into the field of personalized medicine, cell and gene therapies, and commercial-scale manufacturing vs. near-patient production and the predicted paradigm shift.
  • Interviews with:
    • Tony Hitchcock, Technical Director, Cobra Biologics
    • Jerold Martin, Sr. V.P. Global Scientific Affairs, Biopharmaceuticals, Pall Corporation
    • Arnaud Schmutz, General Manager, Sourcin
    • Nigel Smart, Managing Partner, Smart Consulting Group
    • Keith Thompson, CEO, Cell Therapy Catapult
  • Results Biomanufacturing Capacity Strategies Survey

Table of Contents

Executive Summary


Introduction and Background Information


  • Focus of the Report


  • The History of Biomanufacturing


  • Single-use biomanufacturing
    • The advent of single-use biomanufacturing, history, and impact
    • Current state of market and implementation
    • Advantages of single-use technologies:
      • Regulatory Challenges
      • Obsolete safety testing methods
    • Conclusion:
      • The importance of flexible and reactive biomanufacturing
      • Strong business case...but what of implementation and reality?


Biomanufacturing Capacity Strategies, Opportunities, and Challenges


  • Strategies to increase capacity and flexibility
    • Offshoring


  • External Factors Affecting Capacity, Challenges, and Opportunities


  • Operational Excellence and Cost Reduction


  • The Future of the Biomanufacturing Industry and Profession


Biomanufacturing Capacity Innovation as a Solution to Biotechnology Industry Challenges


  • How Market Trends and Predictions Will Affect the Production Paradigm
  • Industry Interview Transcripts
    • Tony Hitchcock
    • Jerold Martin
    • Arnaud Schmutz
    • Nigel Smart
    • Keith Thompson
  • Survey Results
  • Results from Insight Pharma Reports Survey on Biomanufacturing Capacity Strategies
  • References

About Cambridge Healthtech Institute


  • Table 2.1 Regulations in EU Member States regarding hES1 cell research
  • Table 5.1: Factors Influencing Capacity and Flexibility Needs


  • Figure 4.1: Levels of Increase in Biomanufacturing by 2020
  • Figure 4.2: Manufacturing Capacity Strategies Overview
  • Figure 4.3: Modular Facilities Implementation
  • Figure 4.4: Single-Use Technology Implementation
  • Figure 4.5: Outsourcing Implementation
  • Figure 4.6: Offshoring Implementation
  • Figure 5.1: Factors Driving Biomanufacturing Capacity Needs
  • Figure 5.2: Biomanufacturing challenges 2015-2020
  • Figure 8.1: BioPharma Strategy - New Paradigm
Back to Top